---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016686"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:07:20.621733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Q1 2023 revenue $9.8M, up 24% YoY; turns profitable

## Summary
- Net revenue $9.8M (+24% YoY); test volume up ~20% to record levels.
- Income from continuing ops $0.4M vs loss of $1.1M; operating income $0.7M vs loss $1.0M.
- Adjusted EBITDA $1.2M vs -$0.3M; cash balance $5.6M vs $2.9M a year ago.
- Added 41.9M covered lives via 8 new/updated commercial contracts in Q1.
- Gross profit margin improved to 61% from 59% YoY.

## SEC filing metadata
- accession: 0001493152-23-016686
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315223016686/0001493152-23-016686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315223016686/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016686
- JSON: https://secwatch.observer/filing/0001493152-23-016686.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016686.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2023 results: revenue $9.8 million.
  - Period: first quarter ended March 31, 2023
  - Revenue: $9.8 million
  - Result: reported results
  source text: today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update. First quarter Net Revenue was $9.8 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315223016686/0001493152-23-016686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.